Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2014

01.09.2014 | special report

Challenges with overall survival as an endpoint for efficacy assessment in first line metastatic breast cancer randomized controlled clinical trials and the investigation of truncated overall survival as an alternative endpoint

verfasst von: Colin Neate, MSc, Alexander Strasak, PhD, Hans Ulrich Burger, PhD, Barbara Tong, PhD, Lee Kaiser, PhD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Overall survival (OS) remains the gold standard to assess treatment benefit in randomized controlled clinical trials (RCT) of advanced cancer. In first line metastatic breast cancer (1 L MBC) where survival typically is several years instead of months, it is increasingly seen that OS-treatment effects dilute over time, with later line therapies strongly influencing OS analyses. We investigate truncated OS (i.e., truncating deaths and follow-up beyond a certain time point from randomization) as a potential alternative endpoint to OS.

Methods

We reanalyze data from two RCTs in 1 L MBC to illustrate how OS results can be driven by early treatment effects. We flexibly model the hazard ratio (HR) according to time since randomization. We conduct simulations to characterize the impact of number of events, sample-size, and recruitment on the power of the log-rank test for OS and for truncated OS considering truncation at 12, 18, or 24 months in presence of non-proportional hazards (non-PH).

Results

The impact of non-PH on the power of a log-rank test for OS may be severe and the power for a truncated OS analysis is higher in situations of non-PH. Statistically significant OS benefit is unlikely to be demonstrated with a log-rank test unless treatment effect is very strong, long-lasting, or only short-term follow-up is included.

Conclusion

Compared with the classical OS endpoint, truncated OS may provide the treating physicians, prescribers, and payers with a more accurate and less biased estimate of treatment benefit more directly attributable to the treatment under investigation.
Literatur
1.
Zurück zum Zitat Sargent DJ, Hayes DF. Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol. 2008;26:1922–23.PubMedCrossRef Sargent DJ, Hayes DF. Assessing the measure of a new drug: Is survival the only thing that matters? J Clin Oncol. 2008;26:1922–23.PubMedCrossRef
2.
Zurück zum Zitat D’Agostino RB. Changing endpoints in breast-cancer drug approval: the Avastin story. N Engl J Med. 2011;365:e2.CrossRef D’Agostino RB. Changing endpoints in breast-cancer drug approval: the Avastin story. N Engl J Med. 2011;365:e2.CrossRef
3.
Zurück zum Zitat Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary endpoint in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol. 2004;15:545–9.PubMedCrossRef Di Leo A, Buyse M, Bleiberg H. Is overall survival a realistic primary endpoint in advanced colorectal cancer studies? A critical assessment based on four clinical trials comparing fluorouracil plus leucovorin with the same treatment combined either with oxaliplatin or with CPT-11. Ann Oncol. 2004;15:545–9.PubMedCrossRef
4.
Zurück zum Zitat Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29:2439–42.PubMedCrossRefPubMedCentral Korn EL, Freidlin B, Abrams JS. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies. J Clin Oncol. 2011;29:2439–42.PubMedCrossRefPubMedCentral
5.
Zurück zum Zitat Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–9.PubMedCrossRefPubMedCentral Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–9.PubMedCrossRefPubMedCentral
6.
Zurück zum Zitat Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28:1958–62.PubMedCrossRef Saad ED, Katz A, Buyse M. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. J Clin Oncol. 2010;28:1958–62.PubMedCrossRef
7.
Zurück zum Zitat Hurvitz SA. Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint. Cancer Treat Rev. 2011;37:495–504.PubMedCrossRef Hurvitz SA. Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint. Cancer Treat Rev. 2011;37:495–504.PubMedCrossRef
8.
Zurück zum Zitat Food and Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2007. Food and Drug Administration. Guidance for Industry. Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Rockville: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), May 2007.
9.
Zurück zum Zitat Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive endpoint in cancer clinical trials. Cancer J. 2009;15:401–5.PubMedCrossRef Driscoll JJ, Rixe O. Overall survival: still the gold standard: why overall survival remains the definitive endpoint in cancer clinical trials. Cancer J. 2009;15:401–5.PubMedCrossRef
10.
Zurück zum Zitat Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as endpoints of drug efficacy. Cancer J. 2009;15:395–400.PubMedCrossRef Zhuang SH, Xiu L, Elsayed YA. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as endpoints of drug efficacy. Cancer J. 2009;15:395–400.PubMedCrossRef
11.
Zurück zum Zitat Gill S, Berry S, Biagi J, Butts C, Buyse M, Chen E, Jonker D, Mărginean C, Samson B, Stewart J, Thirlwell M, Wong R, Maroun JA. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol. 2011;18(Suppl 2):S5–10.PubMedPubMedCentral Gill S, Berry S, Biagi J, Butts C, Buyse M, Chen E, Jonker D, Mărginean C, Samson B, Stewart J, Thirlwell M, Wong R, Maroun JA. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol. 2011;18(Suppl 2):S5–10.PubMedPubMedCentral
12.
Zurück zum Zitat Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15:386–94.PubMedCrossRef Lebwohl D, Kay A, Berg W, Baladi JF, Zheng J. Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009;15:386–94.PubMedCrossRef
13.
Zurück zum Zitat Tuma R. Progression-free survival remains debatable endpoint in cancer trials. J Natl Cancer Inst. 2009;101:1439–41.PubMedCrossRef Tuma R. Progression-free survival remains debatable endpoint in cancer trials. J Natl Cancer Inst. 2009;101:1439–41.PubMedCrossRef
14.
Zurück zum Zitat Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol. 2008;26:1987–92.PubMedCrossRef Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Lück HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate endpoints in metastatic breast cancer. J Clin Oncol. 2008;26:1987–92.PubMedCrossRef
15.
Zurück zum Zitat Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol. 2011 Dec 10;29(35):4719–20.CrossRef Buyse M, Sargent DJ, Saad ED. Survival is not a good outcome for randomized trials with effective subsequent therapies. J Clin Oncol. 2011 Dec 10;29(35):4719–20.CrossRef
16.
Zurück zum Zitat Fleming TR, Rothman MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009;17:2874–80.CrossRef Fleming TR, Rothman MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol. 2009;17:2874–80.CrossRef
17.
Zurück zum Zitat Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US. Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30:1705–11.PubMedCrossRefPubMedCentral Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R. US. Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol. 2012;30:1705–11.PubMedCrossRefPubMedCentral
18.
Zurück zum Zitat Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–92.PubMedCrossRef Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783–92.PubMedCrossRef
19.
Zurück zum Zitat Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O’Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265–74.PubMedCrossRef Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, Kennedy J, O’Byrne K, Conte P, Green M, Ward C, Mayne K, Extra JM. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265–74.PubMedCrossRef
20.
Zurück zum Zitat Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer;2000.CrossRef Therneau TM, Grambsch PM. Modeling survival data: extending the Cox model. New York: Springer;2000.CrossRef
21.
Zurück zum Zitat Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83:596–610.CrossRef Cleveland WS, Devlin SJ. Locally weighted regression: an approach to regression analysis by local fitting. J Am Stat Assoc. 1988;83:596–610.CrossRef
22.
Zurück zum Zitat Cleveland WS, Devlin SJ, Grosse E. Regression by local fitting: methods, properties, and computational algorithms. J Econom. 1988;37:87–114.CrossRef Cleveland WS, Devlin SJ, Grosse E. Regression by local fitting: methods, properties, and computational algorithms. J Econom. 1988;37:87–114.CrossRef
23.
Zurück zum Zitat Hastie TJ, Tibshirani RJ. Generalized additive models. New York: Chapman & Hall;1990. Hastie TJ, Tibshirani RJ. Generalized additive models. New York: Chapman & Hall;1990.
24.
Zurück zum Zitat Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994;13:1045–62.PubMedCrossRef Hess KR. Assessing time-by-covariate interactions in proportional hazards regression models using cubic spline functions. Stat Med. 1994;13:1045–62.PubMedCrossRef
Metadaten
Titel
Challenges with overall survival as an endpoint for efficacy assessment in first line metastatic breast cancer randomized controlled clinical trials and the investigation of truncated overall survival as an alternative endpoint
verfasst von
Colin Neate, MSc
Alexander Strasak, PhD
Hans Ulrich Burger, PhD
Barbara Tong, PhD
Lee Kaiser, PhD
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0164-6

Weitere Artikel der Ausgabe 3/2014

memo - Magazine of European Medical Oncology 3/2014 Zur Ausgabe